Per the telehealth consent published by OpenLoop Healthcare Partners, PC, the FDA does not approve, review, or evaluate compounded products for safety, effectiveness, or quality
These patches aim to deliver medication continuously, maintaining steady drug levels whilst avoiding the need for weekly or daily injections
The supplement has research studies to back it up, even better if there is clinical research using that supplement specifically
5, Ousia applied for a sterile compounding license in March 2024, but it was never granted
Reducing food intake and extending satiety are significant for weight management and loss
Type 2 Diabetes and MASH Research Separate Phase 2 trials have evaluated retatrutide in participants with type 2 diabetes, where it demonstrated excellent glycemic control with substantial HbA1c reductions (mean reductions of 1.8-2.0% from baselines around 8%), along with impressive weight loss similar to that seen in non-diabetic participants